10 Apr, 2021 New Analyses of OXLUMO® (lumasiran) ILLUMINATE-A Results at the National Kidney Foundation Virtual Spring Clinical Meetings
During the National Kidney Foundation Virtual Spring Clinical Meetings, we presented post hoc subgroup analyses from the ongoing ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran) in patients with primary hyperoxaluria type 1, showing a lowering of 24-hour urinary oxalate (UOx) regardless of crystallization inhibitor use, hydration status, and genotype. The reduction in 24-hour UOx was sustained through Month 12.
Saland, et al. “Lumasiran lowered urinary oxalate in patients with primary hyperoxaluria type 1 irrespective of pyridoxine use, hydration status, and genotype in the Phase 3 clinical trial ILLUMINATE-A.”
Additionally, we presented pooled data from lumasiran clinical trials, demonstrating a statistically significant positive correlation with similar intra-patient variability between 24-hour UOx excretion and spot urinary oxalate:creatinine (UOx:Cr) ratio. These results indicate that spot UOx:Cr ratio is a reliable parameter for assessing oxalate excretion and response to lumasiran treatment in PH1 patients and can serve as an alternative to 24-hour urine collection.